Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher." Who doesn't like betting on fast-moving trending stocks? But determining the right entry point isn't easy. Often, these stocks lose momentum once their valuation moves ...

PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will report financial results for the second quarter of 2024 and provide a business update on Tuesday, August 13, 2024, before the market opens. The press release will be available in the In ...

Company to initiate Phase 3 VERSATILE-003 trial in Q4 2024 Conference Call Today at 8:00 a.m. Eastern Time PRINCETON, N.J., Aug. 01, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) ("PDS Biotech" or the "Company"), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that it has received the official minutes from its meeting with the U.S. Food and Drug Administratio ...

Core Viewpoint - PDS Biotechnology Corporation is set to provide a clinical program update on August 1, 2024, focusing on its immunotherapy developments and upcoming pivotal clinical trials [1][2]. Company Overview - PDS Biotechnology is a late-stage immunotherapy company dedicated to enhancing the immune system's ability to target and eliminate cancers, as well as developing vaccines for infectious diseases [2]. - The company plans to initiate a pivotal clinical trial in 2024 for its lead program targeting advanced HPV16-positive head and neck squamous cell cancers [2]. Clinical Development - The lead investigational targeted immunotherapy, Versamune® HPV, is being developed in combination with a standard immune checkpoint inhibitor and in a triple combination with PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), along with a standard immune checkpoint inhibitor [2].

Core Insights - Precision Drilling reported quarterly earnings of $1.05 per share, exceeding the Zacks Consensus Estimate of a loss of $0.62 per share, but down from $1.21 per share a year ago [4] - The company achieved revenues of $313.71 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 1.53%, although this represents a decline from $316.89 million year-over-year [2] - Precision Drilling's stock has increased approximately 31.1% since the beginning of the year, outperforming the S&P 500's gain of 14.5% [3] Earnings Performance - The earnings surprise for the latest quarter was 269.35%, following a previous quarter where earnings were $1.88 per share against an expectation of $2 per share, resulting in a surprise of -6% [1] - Over the last four quarters, the company has surpassed consensus EPS estimates two times [5] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.36 on revenues of $358.99 million, and for the current fiscal year, it is $6.03 on revenues of $1.47 billion [10] - The estimate revisions trend for Precision Drilling is currently unfavorable, leading to a Zacks Rank 5 (Strong Sell) for the stock, indicating expected underperformance in the near future [9] - The Oil and Gas - Drilling industry is ranked in the bottom 18% of over 250 Zacks industries, suggesting potential challenges for stocks in this sector [11]

Precision Drilling Corporation ("Precision" or the "Company") (TSX:PD; NYSE:PDS) delivered outstanding second quarter financial results and demonstrated its cash flow potential. During the quarter, Precision generated cash flow from operations of $174 million, allowing it to reduce debt by $102 million, increase its cash position by $17 million, return $23 million to shareholders through share buybacks, and invest $38 million in its fleet. For 2024, Precision remains firmly committed to repaying debt betwee ...

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION AND STATEMENTS We believe that the Net Debt (long-term debt less cash, as reported in our Condensed Interim Consolidated Statements of Financial Position) to Adjusted EBITDA ratio provides an indication of the number of years it would take for us to repay our debt obligations. As at January 1, 2023, accounts payable and accrued liabilities increased by $12 million and non-current share-based compensation liability decreased by $12 million. As at Dec ...

Core Viewpoint - Precision Drilling (PDS) is anticipated to report a year-over-year increase in earnings despite lower revenues, with a consensus EPS estimate of $6.89 per share, reflecting a significant increase of +469.4% compared to the previous year [1][3]. Earnings Expectations - The upcoming earnings report is expected to show revenues of $308.87 million, which is a decrease of 2.5% from the same quarter last year [14]. - The consensus EPS estimate has been revised down by 9.93% over the last 30 days, indicating a reassessment by analysts [14]. Earnings Surprise Prediction - The Most Accurate Estimate for Precision Drilling is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +109%, suggesting a bullish outlook from analysts [7]. - A positive Earnings ESP is generally a strong predictor of an earnings beat, especially when combined with a favorable Zacks Rank [16]. Historical Performance - Over the last four quarters, Precision Drilling has beaten consensus EPS estimates two times, which may influence future earnings expectations [10]. - In the last reported quarter, the company was expected to post earnings of $2 per share but delivered only $1.88, resulting in a surprise of -6% [18]. Stock Movement Potential - The stock may experience upward movement if the upcoming earnings report exceeds expectations, while a miss could lead to a decline [13].

About Precision Precision is a leading provider of safe and environmentally responsible High Performance, High Value services to the energy industry, offering customers access to an extensive fleet of Super Series drilling rigs. Precision has commercialized an industry-leading digital technology portfolio known as AlphaTM that utilizes advanced automation software and analytics to generate efficient, predictable, and repeatable results for energy customers. Our drilling services are enhanced by our EverGree ...

Core Points - Precision Drilling Corporation announced the successful election of all eight nominee directors at its 2024 Annual and Special Meeting of Shareholders, with seven being independent [1] - The voting results showed high approval rates for the nominee directors, with William T. Donovan receiving 98.58% of votes in favor and Kevin A. Neveu receiving 99.04% [2] - Michael R. Culbert will retire from the Board after serving since 2017, while Alice L. Wong has been welcomed to the Board, bringing over 35 years of experience in the nuclear fuel industry [3] Company Overview - Precision Drilling is a leading provider of safe and environmentally responsible services to the energy industry, offering access to a fleet of Super Series drilling rigs [5] - The company has developed an industry-leading digital technology portfolio known as AlphaTM, which utilizes advanced automation software and analytics for efficient results [5] - Precision also provides well service rigs, camps, and rental equipment, supported by a comprehensive mix of technical services and skilled personnel [5] Additional Information - Precision Drilling is headquartered in Calgary, Alberta, Canada, and is listed on the Toronto Stock Exchange under the symbol "PD" and on the New York Stock Exchange under "PDS" [6]